News

JST-018 orthopoxvirus antibody enters phase 1 trial under $123.9M defense contract with Just-Evotec Biologics for warfighter protection.

BridgeBio shifts BBO-8520 focus to KRAS combinations in second-line NSCLC, building on a 63% response rate from monotherapy.

Novartis triggers $50M milestone payment as MRT-6160 enters Phase 2 for Sjögren's disease, advancing VAV1 degrader development.

Mosliciguat advances to Phase 3 PHrontier Trial after PHocus Study shows 20% pulmonary vascular resistance reduction in PH-ILD patients.

Clinical trial sites should establish data infrastructure before deploying AI tools, according to industry experts and recent guidance on...

Ascendis will present sentinel cohort data from the reACHin Trial of navepegritide infant trial at ESPE 2026, extending the...

Tekton Research sites enrolled 60 participants in Phase 2 obesity trial, tripling their combined enrollment goal and demonstrating strong...

Myriad bioscaffolds demonstrated a 0.7% deep infection rate in soft tissue reconstruction across 411 patients, significantly below historical benchmarks.

Clover's RSV-hMPV vaccine produced 6-to-9-fold antibody rises in Phase 2, with no immune interference and strong safety. Candidate targets...

FDA guidance expands cancer trial eligibility to include patients with ECOG PS 2, reshaping enrollment models and operational requirements...